Related Articles
Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
Feasibility of concervative breast surgery and intraoperative radiation therapy for early breast cancer: A single-center, open, non-randomized, prospective pilot study
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21‑gene recurrence score of 26‑30
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit